Psychedelika in der Psychiatrie – Entwicklungen und die Stellung in Deutschland

Zusammenfassung

In den letzten Jahren erlebte die klinische Forschung zur therapeutischen Wirksamkeit von Psychedelika eine Art Renaissance. Der aktuelle Stand wissenschaftlicher Erkenntnisse zur Wirksamkeit bei verschiedenen psychiatrischen Indikationen, wie auch die bereits unter bestimmten Voraussetzungen genehmigungsfähige Anwendung einiger psychedelischer Substanzen in der klinischen Praxis in manchen Ländern der Welt, legen die Möglichkeit einer zukünftigen Anwendung im klinischen Setting auch in Deutschland nahe. Dabei steht das Feld noch vor großen Herausforderungen inklusive der Notwendigkeit einer kritischen Gestaltung der Rahmenbedingungen für einen möglichen klinischen Einsatz. In diesem Artikel wird auf die historischen Hintergründe der klinischen Anwendung von Psychedelika eingegangen, um dann Aspekte wie Psychophänomenologie, Wirkmodelle, mögliche Indikationen und Pharmakosicherheit zu beleuchten. Anschließend wird der aktuelle Stand der Forschung und auch der Organisation von Fachgesellschaften in Deutschland im historischen und internationalen Kontext betrachtet, wie auch kritische Aspekte und noch zu klärende Fragen in dem Themenfeld.

Abstract

Clinical research on the therapeutic efficacy of psychedelics is currently experiencing a renaissance. Available scientific evidence on their efficacy in various psychiatric conditions, as well as their legally approved use in some countries of the world, show the possibility of their future application in clinical practice also in Germany. The field is facing substantial challenges that have to be addressed, such as defining and setting a suitable clinical frame. This manuscript deals with the historical background of the clinical application of psychedelics, as well as the psycho-phenomenology, modes of action, possible indications and aspects of safety. The current research status in Germany and the organization of professional societies are discussed in a historical and international context and attention is drawn to unresolved critical issues in the field.

Schlüsselwörter

Augmentierte Psychotherapie - Depression - PTSD - Psilocybin - LSD - MDMA

Key words

augmented psychotherapy - depression - PTSD - Psilocybin - LSD - MDMA

Publication History

Received: 04 July 2022

Accepted after revision: 11 October 2022

Article published online:
04 January 2023

• Literatur

• 1 Davis AK, Barrett FS, May DG. et al. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry 2021; 78: 481-489
• 2 Boldrini M, Canoll PD, Klein RS. How COVID-19 Affects the Brain. JAMA Psychiatry 2021; 78: 682-683
• 3 Altmetric – Effcts of Psilocybin-Assisted Therapy on Major Depressive Disorder
• 4 Lewin Louis. Über Anhalonium Lewinii. Archiv für experimentelle Pathologie und Pharmakologie 1887; 24: 411
• 5 Heffter A. Ueber Pellotin. Therapeutische Monatshefte 1896; 10: 327-328
• 6 Lewin L. Phantastica – Die betäubenden und erregenden Genußmittel – Für Ärzte und Nichtärzte. Berlin. 1924
• 7 Beringer K. Der Mescalinrausch. Seine Geschichte und Erscheinungsweise. Berlin. 1927
• 8 Hofmann A. LSD – mein Sorgenkind. Stuttgart: Clett-Kotta,; 1979
• 9 Stoll WA. Lysergsäure-Diäthylamid, ein Phantasticum aus der Mutterkorngruppe. Archiv für Neurologie und Psychiatrie 1947; 60: 279-323
• 10 Leuner H. Halluzinogene. Psychische Grenzzustände in Therapie und Forschung. Bern: Verlag Hans Huber; 1981
• 11 Rucker JJH, Iliff J, Nutt DJ. Psychiatry & the psychedelic drugs. Past, present & future. Neuropharmacology 2018; 142: 200-218
• 12 Passie T. The early use of MDMA (‚Ecstasy’) in psychotherapy (1977–1985). Drug, Science and Law 2018; 4: 1-19
• 13 Nichols DE. Differences between the Mechanism of Action of MDMA, MDBD and the Classic Hallucinogens. Journal of Psychoactive Drugs 1986; 18: 305-313
• 14 Passie T, Benzenhöfer U. MDA, MDMA, and other "mescaline-like" substances in the US military’s search for a truth drug (1940s to 1960s). Drug Test Anal 2018; 72-80
• 15 Gasser P. Die psycholytische Psychotherapie in der Schweiz von 1988-1993. Eine katamnestische Erhebung. Schweizer Archiv für Neurologie und Psychiatrie 1996; 147: 59-65
• 16 Vollenweider FX, Kometer M. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci 2010; 11: 642-651
• 17 Gründer G, Brand M, Kärtner L. et al. Sind Psychedelika schnell wirksame Antidepressiva? [Are psychedelics fast acting antidepressant agents?]. Nervenarzt 2022; 93: 254-262
• 18 Mertens LJ, Koslowski M, Betzler F. et al. Methodological Challenges in Psychedelic Drug Trials: Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression (EPIsoDE) – Rationale and Study Design. Neurosci Applied 2022; 1: 100104
• 19 Mitchell JM, Bogenschutz M, Lilienstein A. et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med 2021; 27: 1025-1033
• 20 Majić T, Jungaberle H, Schmidt TT. et al. Psychotherapie mit adjuvanter Gabe von serotonergen psychoaktiven Substanzen – Möglichkeiten und Hindernisse [Psychotherapy with Adjuvant use of Serotonergic Psychoactive Substances: Possibilities and Challenges]. Fortschr Neurol Psychiatr 2017; 85: 383-392
• 21 Sanacora G, Frye MA, McDonald W. et al. American Psychiatric Association (APA) Council of Research Task Force on Novel Biomarkers and Treatments. A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. JAMA Psychiatry 2017; 74: 399-405
• 22 Dore J, Turnipseed B, Dwyer S. et al. Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and Outcomes in Three Large Practices Administering Ketamine with Psychotherapy. J Psychoactive Drugs 2019; 51: 189-198
• 23 Palhano-Fontes F, Soares BL, Galvão-Coelho NL, et al. Ayahuasca for the Treatment of Depression. Curr Top Behav Neurosci. 2021. 10.1007/7854_2021_277. Epub ahead of print
• 24 Reiff CM, Richman EE, Nemeroff CB. et al. the Work Group on Biomarkers and Novel Treatments, a Division of the American Psychiatric Association Council of Research. Psychedelics and Psychedelic-Assisted Psychotherapy. Am J Psychiatry 2020; 177: 391-410
• 25 Dittrich A. The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry. 1998; 31: 80-84
• 26 Schmidt TT, Berkemeyer H. The Altered States Database: Psychometric Data of Altered States of Consciousness. Front Psychol 2018; 9: 1028
• 27 Passie T, Scharfetter C. A taxonomy of ecstatic states in the context of psychotherapy with psychedelic substances. Journal of Consciousness Studies 2019; 256: 155-178
• 28 Holze F, Vizeli P, Ley L. et al. Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology 2021; 46: 537-544
• 29 Holze F, Ley L, Müller F, Becker AM. et al. Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology 2022;
• 30 Hamill J, Hallak J, Dursun SM. et al. Ayahuasca: Psychological and Physiologic Effects, Pharmacology and Potential Uses in Addiction and Mental Illness. Curr Neuropharmacol 2019; 17: 108-128
• 31 Kraehenmann R, Preller KH, Scheidegger M. et al. Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers. Biol Psychiatry 2015; 78: 572-581
• 32 Müller F, Lenz C, Dolder PC. et al. Acute effects of LSD on amygdala activity during processing of fearful stimuli in healthy subjects. Transl Psychiatry 2017; 7: e1084
• 33 Mertens LJ, Wall MB, Roseman L. et al. Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression. J Psychopharmacol 2020; 34: 167-180
• 34 Müller F, Lenz C, Dolder P. et al. Increased thalamic resting-state connectivity as a core driver of LSD-induced hallucinations. Acta Psychiatr Scand 2017; 136: 648-657
• 35 Müller F, Dolder PC, Schmidt A. et al. Altered network hub connectivity after acute LSD administration. Neuroimage Clin 2018; 18: 694-701
• 36 Vollenweider FX, Preller KH. Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. Nat Rev Neurosci 2020; 21: 611-624
• 37 Carhart-Harris RL, Erritzoe D, Williams T, Stone JM. et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A 2012; 109: 2138-2143
• 38 Carhart-Harris RL, Muthukumaraswamy S, Roseman L. et al. Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proc Natl Acad Sci U S A 2016; 113: 4853-4858
• 39 Palhano-Fontes F, Andrade KC, Tofoli LF. et al. The psychedelic state induced by ayahuasca modulates the activity and connectivity of the default mode network. PLoS One 2015; 10: e0118143
• 40 Smigielski L, Kometer M, Scheidegger M. et al. Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat. Sci Rep 2019; 9: 14914
• 41 Carhart-Harris RL. How do psychedelics work?. Curr Opin Psychiatry 2019; 32: 16-21
• 42 Wolff M, Evens R, Mertens LJ. et al. Learning to Let Go: A Cognitive-Behavioral Model of How Psychedelic Therapy Promotes Acceptance. Front Psychiatry 2020; 11: 5
• 43 Jungaberle H, Thal S, Zeuch A. et al. Positive psychology in the investigation of psychedelics and entactogens: A critical review. Neuropharmacology. 2018; 142: 179-199
• 44 Davis AK, Barrett FS, Griffiths RR. Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety. J Contextual Behav Sci 2020; 15: 39-45
• 45 Guss J, Krause R, Sloshower J. Yale Manual for Psilocybin-assisted Therapy of Depression. 2020;
• 46 Busch AK, Johnson WC. L.S.D. 25 as an aid in psychotherapy; preliminary report of a new drug. Dis Nerv Syst 1950; 11: 241-243
• 47 Savage C. Lysergic acid diethylamide; a clinical-psychological study. Am J Psychiatry 1952; 108: 896-900
• 48 Sandison RA, Whitelaw JD. Further studies in the therapeutic value of lysergic acid diethylamide in mental illness. J Ment Sci 1957; 103: 332-343
• 49 Smith CM. A new adjunct to the treatment of alcoholism: the hallucinogenic drugs. Q J Stud Alcohol 1958; 19: 406-417
• 50 Mithoefer MC, Wagner MT, Mithoefer AT. et al. Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study. J Psychopharmacol 2013; 27: 28-39
• 51 De Gregorio D, Comai S, Posa L. et al. d-Lysergic Acid Diethylamide (LSD) as a Model of Psychosis: Mechanism of Action and Pharmacology. Int J Mol Sci 2016; 17: 1953
• 52 Carhart-Harris RL, Bolstridge M, Rucker J. et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry 2016; 3: 619-627
• 53 Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M. et al. Trial of Psilocybin versus Escitalopram for Depression. N Engl J Med 2021; 384: 1402-1411
• 54 Bogenschutz MP, Forcehimes AA, Pommy JA. et al. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol 2015; 29: 289-299
• 55 Krediet E, Bostoen T, Breeksema J. et al. Reviewing the Potential of Psychedelics for the Treatment of PTSD. Int J Neuropsychopharmacol 2020; 23: 385-400
• 56 Bird CIV, Modlin NL, Rucker JJH. Psilocybin and MDMA for the treatment of trauma-related psychopathology. Int Rev Psychiatry 2021; 33: 229-249
• 57 Nichols DE. Psychedelics. Pharmacol Rev. 2016; 68(2): 264-355. doi: 10.1124/pr.115.011478. Erratum in: Pharmacol Rev. 2016; 68(2): 356
• 58 Han B, Compton WM, Jones CM. et al. Methamphetamine Use, Methamphetamine Use Disorder, and Associated Overdose Deaths Among US Adults. JAMA Psychiatry 2021; 78: 1329-1342
• 59 Dos Santos RG, Bouso JC, Alcázar-Córcoles MÁ. et al. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews. Expert Rev Clin Pharmacol 2018; 11: 889-902
• 60 NIDA (National Institute on Drug Abuse): Hallucinogens. April 22, 2019 https://www.drugabuse.gov/publications/drugfacts/hallucinogens
• 61 Müller F, Kraus E, Holze F. et al. Flashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants. Psychopharmacology (Berl). 2022
• 62 Anderson BT, Danforth AL, Grob CS. Psychedelic medicine: safety and ethical concerns. Lancet Psychiatry 2020; 10: 829-830
• 63 Gründer G, Jungaberle H. The Potential Role of Psychedelic Drugs in Mental Health Care of the Future. Pharmacopsychiatry 2021; 54: 191-199
• 64 Tai SJ, Nielson EM, Lennard-Jones M. et al. Development and Evaluation of a Therapist Training Program for Psilocybin Therapy for Treatment-Resistant Depression in Clinical Research. Front Psychiatry 2021; 12: 586682